drugset / Trial / NCT07444268

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

NCT07444268

Phase 1 Recruiting 8 enrolled Sumitomo Pharma America, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.

Timeline

Start
2026-03-26
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzomenib Small molecule Oral